CMS identifies Medicare billing codes for combination antibody therapy

The Centers for Medicare & Medicaid Services has identified Healthcare Common Procedure Coding System codes for billing Medicare for the combination monoclonal antibodies bamlanivimab and etesevimab, made by Eli Lilly and Co.

The Food and Drug Administration this month authorized administering the monoclonal antibodies together to treat patients 12 and older with mild-to-moderate COVID-19 who are at high risk for progressing to severe disease but not hospitalized or on oxygen therapy. The emergency use authorization also authorizes the treatment for patients 65 or older with certain chronic medical conditions.